Key Highlights
- $6.95M Seed Financing led by SOSV, We Venture Capital, and others.
- CKM™ platform provides continuous potassium monitoring for cardio-kidney-metabolic diseases.
- Clinical studies underway for patients with CKD and ESRD.
- Transforming care by enabling timely data-driven decisions to prevent dyskalemia.
- Investors include SOSV, We Venture Capital, Tenmile, and others.
Source: Business Wire
Notable Quotes
- “The team’s exceptional focus and relentless execution inspire confidence, and we are excited to continue to support them as they move into clinical validation.” – Mohan S. Iyer, General Partner at SOSV
- “We Venture Capital have been impressed by this true breakthrough in electrolyte sensing capability, which will fulfil a critical gap in the current care continuum for many patients at risk from dyskalemia.” – Dr. Louise Warme, Head at We Venture Capital
- “The ability to continuously monitor potassium will enable better data-driven decision-making for patients with late-stage chronic kidney disease or on dialysis, not only improving outcomes for these patients but saving health systems considerable costs.” – Dr. Steve Burnell, Managing Director at Tenmile
Why This Matters
Proton Intelligence’s groundbreaking CKM™ platform represents a significant technological leap in cardio-kidney-metabolic care. By addressing the critical need for real-time potassium monitoring, the company is poised to save lives, improve patient outcomes, and reduce healthcare costs. This seed funding milestone not only validates the team’s vision but also sets the stage for meaningful clinical trials that could redefine standards of care. As CKM™ moves toward commercial viability, its potential impact on patients and the healthcare system cannot be overstated.
